161 Fort Washington AvenueNew York, NY 10032
Overview of Dr. Reshef
Dr. Ran Reshef is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Tel Aviv University Sackler and has been in practice 19 years. Dr. Reshef accepts several types of health insurance, listed below. He is one of 369 doctors at New York-Presbyterian Hospital and one of 121 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He also speaks multiple languages, including Hebrew. He has more than 100 publications and over 500 citings.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2007 - 2009
Tel Aviv University SacklerClass of 1998
Certifications & Licensure
NY State Medical License 2015 - 2026
PA State Medical License 2007 - 2016
Clinical Trials
- Phase II Maraviroc for GVHD Prevention Start of enrollment: 2013 Feb 01
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study.Matthew J Frigault, Richard T Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah
Blood. 2025-03-16 - Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer
Blood Advances. 2025-03-15 - Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
Journal of Clinical Oncology. 2025-03-10
Journal Articles
- Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica
Abstracts/Posters
- The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host DiseaseRan Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...Ran Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant RecipientsRan Reshef, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Certain Donors with High T Cell Counts Make a Better Match for Stem-Cell Transplant Patients, Study SuggestsJune 8th, 2015
Professional Memberships
- Member
Other Languages
- Hebrew
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
Amerihealth HMO
AmeriHealth PPO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Health Net HMO - Employer Group
HealthAmerica HealthAssurance PPO
Horizon BCBS Direct AccessHorizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Humana ChoiceCare Network PPO
IBC Keystone HMO / POS
IBC Personal Choice PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
